- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06624904
Losartan og sosial prosessering
Effektene av enkeltdose losartan på sosial prosessering hos friske voksne: en randomisert kontrollert studie
This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
While renin-angiotensin mechanisms have been implicated in physiological disease, such as hypertension and stroke, the discovery of a local brain renin-angiotensin system (RAS) in the 1970s brought into question whether the RAS may play a role in psychiatric disorders too. Recent work has supported this link, with several studies reporting RAS influence on aversive learning, stress response to traumatic stimuli, and fear extinction.
Despite these promising results, studies have yet to fully explore the influence of the RAS and losartan on social processes. It is plausible that the RAS may be involved in social functioning, as recent work reported that losartan reduces sensitivity to social punishment in healthy volunteers. Such an effect of losartan may have broad relevance for psychopathology, as impairment to social functioning is present across a range of psychiatric disorders.
In this double-blind, randomized between-group study, the investigators will examine the effects of a single dose of losartan (50mg) versus placebo on social processing in N=68 healthy volunteers. Following a one-hour waiting period, participants will complete a set of computer tasks investigating social processes reported to be sensitive to psychopathology. Specifically, participants will complete the Approach Avoidance Task which assesses social approach and avoidance behaviour in response to various facial expressions via joystick movement, the Interpretation Inflexibility Task which evaluates cognitive flexibility in a social context, the Social Learning Trust Game which evaluates social learning through a trust game between participant investors and realistic trustees, and Cyberball, which probes response to social rejection. Results from this study will provide more insight on the potential role of the RAS in social cognitive processing in humans, which could lead to an improved mechanistic understanding of emotional disorders that are marked by social impairment.
Studietype
Registrering (Faktiske)
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiesteder
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannia, OX37JX
- Warneford Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Willing and able to provide informed consent
- Aged 18-50 years
- Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
- Non- or light-smoker (5 cigarettes a day, if vaping: less than 50 puffs)
- BMI between 18 - 30
Exclusion Criteria:
- Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder
- First-degree family member with severe psychiatric illness (including psychosis, bipolar disorder, unipolar psychotic depression).
- CNS-medication last 6 weeks (including as part of another study)
- Current blood pressure or other heart medication, including aliskiren and beta blockers)
- Diagnosis of intravascular fluid depletion or dehydration
- History of angioedema
- Impaired kidney function (based on self-report)
- Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions)
- Lifetime history of epilepsy or other neurological disorder, as established by a professional diagnosis (e.g. autism, ADHD)
- Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
- Significant loss of hearing that is not corrected with a hearing device
- Women: pregnancy (as determined by a urine test, if the participant's pregnancy status is unknown during the in-person visit), breast-feeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Losartan
50 mg single-dose losartan |
Single dose losartan (50 mg), encapsulated identically to placebo.
Andre navn:
|
|
Placebo komparator: Placebo
Microcellulose placebo in identical capsule |
Single tablet encapsulated identically to placebo. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AAT effect score
Tidsramme: 1 hour after capsule intake
|
mean reaction time of the pull trials of a valence category subtracted from the push trials of the same category, yielding a single indicator of approach/avoidance, with positive scores indicating relatively stronger approach and negative scores indicating relatively stronger avoidance |
1 hour after capsule intake
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity to Social Rejection
Tidsramme: 1 hour after capsule intake
|
a) feelings of belonging, control, self-esteem, meaningful existence (on a scale from 1 to 5, with some items reverse coded) as measured on the reflexive and reflective needs-threat scale following Cyberball. |
1 hour after capsule intake
|
|
Social Learning
Tidsramme: 1 hour after capsule intake
|
Social learning rate (early round versus late round investment decisions by generosity condition) |
1 hour after capsule intake
|
|
Interpretation Inflexibility
Tidsramme: 1 hour after capsule intake
|
Within-person revision of biased interpretations: calculated by taking the average of differences between bias scores between stage 3/2 and 2/1. These two differences will be squared before averaging to reflect absolute change (i.e., in either direction), then the square root of the resulting average will be taken. Higher values mean more flexibility in revising prior interpretations. |
1 hour after capsule intake
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- R92661
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .